ArticleJournal of endocrinological investigation2025
Reevaluating potassium supplementation in pediatric DKA: Is routine KPO
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiabetic ketoacidosis (DKA) is a serious complication in pediatric patients with type 1 diabetes, requiring careful management of electrolyte imbalances, particularly for hypokalemia. This study evaluates the clinical outcomes of different potassium supplementation strategies during DKA treatment.
methodsThis retrospective cohort study analyzed pediatric DKA cases treated in a pediatric emergency department over a 13-year period. Outcomes included serum electrolyte imbalances, hyperchloremic acidosis contribution, time to acidosis resolution, and time to transition to subcutaneous (SC) insulin.
resultsA total of 113 pediatric DKA individuals were included, with a median age of 9.23 (± 4.15) years; 58.4% (n = 66) were female. Among these 113 individuals, 36 (31.9%) were administered both potassium chloride (KCL) and potassium phosphate (KPO₄), whereas, 77 (68.1%) were administered KCL exclusively. No significant difference was observed between these two groups in terms of the severity of acidosis, the duration of acidosis recovery, and the incidence of hypokalemia and hyperchloremia.
conclusionThe omission of KPO₄ supplementation in DKA treatment did not increase the risk of hyperchloremic metabolic acidosis, prolong acidosis resolution, delay transition to SC insulin therapy, or cause clinically significant hypophosphatemia. These findings suggest that KCl may be a valid alternative in the management of pediatric diabetic ketoacidosis when KPO₄ is unavailable; however, prospective randomized controlled trials are needed to confirm this observation.
Indexed as
Identifiers
40824470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.